Get the Stockscreener App
8.28
4.39%
-0.38
After Hours:
8.28
Enanta Pharmaceuticals Inc stock is traded at $8.28, with a volume of 223.75K.
It is down -4.39% in the last 24 hours and up +20.70% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$8.66
Open:
$8.57
24h Volume:
223.75K
Relative Volume:
1.29
Market Cap:
$177.01M
Revenue:
$66.59M
Net Income/Loss:
$-104.93M
P/E Ratio:
-1.6727
EPS:
-4.95
Net Cash Flow:
$-96.48M
1W Performance:
-6.44%
1M Performance:
+20.70%
6M Performance:
+13.89%
1Y Performance:
-32.08%
1-Day Range:
$8.25
$8.855
1-Week Range:
$8.245
$9.09
52-Week Range:
$4.09
$13.37
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
8.28 | 178.08M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-09-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-08-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Custom watchlist performance reports with Enanta Pharmaceuticals Inc.July 2025 Patterns & Stock Portfolio Risk Management - Newser
Is Enanta Pharmaceuticals Inc. meeting your algorithmic filter criteriaMarket Movement Recap & AI Enhanced Trading Signals - Newser
Using fundamentals and technicals on Enanta Pharmaceuticals Inc.Trade Entry Report & AI Forecasted Entry/Exit Points - Newser
Real time social sentiment graph for Enanta Pharmaceuticals Inc.July 2025 Trade Ideas & Daily Stock Momentum Reports - Newser
Using R and stats models for Enanta Pharmaceuticals Inc. forecastingPortfolio Profit Report & Daily Chart Pattern Signal Reports - Newser
Can Enanta Pharmaceuticals Inc. hit a new high this monthJuly 2025 Rallies & Real-Time Volume Analysis - Newser
Short interest data insights for Enanta Pharmaceuticals Inc.Market Rally & High Conviction Buy Zone Alerts - Newser
Risk vs reward if holding onto Enanta Pharmaceuticals Inc.Trade Analysis Report & Short-Term Trading Opportunity Alerts - Newser
Sentiment analysis tools applied to Enanta Pharmaceuticals Inc.Weekly Loss Report & Technical Analysis for Trade Confirmation - Newser
Published on: 2025-09-12 05:58:44 - Newser
Using data filters to optimize entry into Enanta Pharmaceuticals Inc.Trade Analysis Summary & Short-Term High Return Strategies - Newser
Tools to monitor Enanta Pharmaceuticals Inc. recovery probabilityMarket Activity Summary & Real-Time Stock Price Movement Reports - Newser
Published on: 2025-09-12 00:32:25 - Newser
Will Enanta Pharmaceuticals Inc. stock go up soonJuly 2025 Drop Watch & Daily Profit Focused Stock Screening - Newser
Nuveen LLC Invests $313,000 in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
Visualizing Enanta Pharmaceuticals Inc. stock with heatmapsJuly 2025 Drop Watch & Free Weekly Watchlist of Top Performers - Newser
How to build a dashboard for Enanta Pharmaceuticals Inc. stockMarket Trend Summary & Detailed Earnings Play Alerts - Newser
Key resistance and support levels for Enanta Pharmaceuticals Inc.Quarterly Portfolio Summary & Community Consensus Trade Alerts - Newser
Ieq Capital LLC Takes $232,000 Position in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
Trexquant Investment LP Has $1.60 Million Stock Position in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
Pattern recognition hints at Enanta Pharmaceuticals Inc. upsideJuly 2025 Institutional & High Win Rate Trade Tips - Newser
Real time pattern detection on Enanta Pharmaceuticals Inc. stockJuly 2025 Pullbacks & Reliable Breakout Forecasts - Newser
Does Enanta Pharmaceuticals Inc. fit your quant trading modelAnalyst Upgrade & Stepwise Trade Execution Plans - Newser
Enanta at Baird Conference: Optimism in Virology and Immunology By Investing.com - Investing.com Canada
PDT Partners LLC Raises Stake in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
What candlestick patterns are forming on Enanta Pharmaceuticals Inc.July 2025 Gainers & Consistent Growth Equity Picks - Newser
Real time breakdown of Enanta Pharmaceuticals Inc. stock performanceJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Is a relief rally coming for Enanta Pharmaceuticals Inc. holdersMarket Sentiment Report & Growth Focused Stock Reports - Newser
How high can Enanta Pharmaceuticals Inc. stock goEntry Point & High Conviction Buy Zone Picks - Newser
Published on: 2025-09-09 23:23:07 - Newser
How to interpret RSI for Enanta Pharmaceuticals Inc. stock2025 EndofYear Setup & Fast Entry High Yield Tips - Newser
Published on: 2025-09-09 17:59:25 - Newser
Enanta Pharmaceuticals at H.C. Wainwright: Strategic Focus on RSV and Immunology - Investing.com Australia
Enanta Pharmaceuticals at H.C. Wainwright: Strategic Focus on RSV and Immunology By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):